This year, Olon’s Daptomycin celebrates its 10th anniversary—and the API supplier group has announced the doubling of its production to meet and exceed global demand for the active ingredient.
 
Daptomycin was one of the first in a new class of antibiotics designed for the treatment of skin infections. Olon manufactures Daptomycin by biomanufacturing—in its Biotech centers that are fully integrated with the company’s global manufacturing network—through an advanced and highly complex fermentation and purification process.
 
The story of Olon Daptomycin began in 2014, with the validation of the first batch. The launch was preceded by investment in research and development to achieve a high level of knowledge of the product and its production process, which led to its improvement in terms of sustainability, guaranteeing a high-quality final product. In the following years, Olon launched in the U.S. and Europe, in parallel with a gradual and steady increase in its market offering. By investing in facilities, it significantly increased its capacity following the growth trend of the global market. The additional expansion milestone announced today will allow the current production capacity to be doubled by 2025 to cover a large proportion of world demand.
 
“Ten years on, thanks to continuous improvement, we continue to remain very competitive in all markets without ever losing our focus on the sustainability of the production process,” explains Giorgio Bertolini, VP R&D at Olon.
 
Daptomycin was the first member of a new class of antibiotics, the cyclic lipopeptides, with a broad spectrum covering Gram-positive pathogens, including multidrug-resistant organisms.